Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment ; volume:13 ; number:3 ; day:15 ; month:6 ; year:2011 ; pages:1-9 ; date:6.2011
Breast cancer research ; 13, Heft 3 (15.6.2011), 1-9, 6.2011
- Creator
-
Giuliano, Mario
- Contributor
-
Giordano, Antonio
Jackson, Summer
Hess, Kenneth R.
De Giorgi, Ugo
Mego, Michal
Handy, Beverly C.
Ueno, Naoto T.
Álvarez, Ricardo H.
De Laurentiis, Michelino
De Placido, Sabino
Valero, Vicente
Hortobagyi, Gabriel N.
Reuben, James M.
Cristofanilli, Massimo
SpringerLink (Online service)
- DOI
-
10.1186/bcr2907
- URN
-
urn:nbn:de:1111-2016032411982
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Giuliano, Mario
- Giordano, Antonio
- Jackson, Summer
- Hess, Kenneth R.
- De Giorgi, Ugo
- Mego, Michal
- Handy, Beverly C.
- Ueno, Naoto T.
- Álvarez, Ricardo H.
- De Laurentiis, Michelino
- De Placido, Sabino
- Valero, Vicente
- Hortobagyi, Gabriel N.
- Reuben, James M.
- Cristofanilli, Massimo
- SpringerLink (Online service)
Other Objects (12)
Prognostic potential of standard laboratory parameters in patients with metastatic renal cell cancer receiving first-line immunotherapy
Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer
Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer
Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer
Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502
Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
Prognostic potential of standard laboratory parameters in patients with metastatic renal cell cancer receiving first-line immunotherapy
Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer
Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer
Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer
Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502
Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
Prognostic potential of standard laboratory parameters in patients with metastatic renal cell cancer receiving first-line immunotherapy
Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer
Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer
Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer
Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502